相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件:
Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名:
MK-591
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- CAS号:
136668-42-3
- 规格:
10 mM * 1 mL/1 mg/5 mg/10 mg/50 mg
| 规格: | 10 mM * 1 mL | 产品价格: | ¥1562.0 |
|---|---|---|---|
| 规格: | 1 mg | 产品价格: | ¥549.0 |
| 规格: | 5 mg | 产品价格: | ¥1209.0 |
| 规格: | 10 mg | 产品价格: | ¥1628.0 |
| 规格: | 50 mg | 产品价格: | ¥7217.0 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
Quiflapon
CAS No. : 136668-42-3
MCE 国际站:Quiflapon
产品活性:Quiflapon (MK-591)是一种选择性和特异性的 FLAP 抑制剂,IC50 为 1.6 nM。Quiflapon 也是一种有效的口服白三烯生物合成 (leukotriene biosynthesis) 抑制剂,在完整的人和诱导的大鼠多形核白细胞 PMNLs 中,其 IC50 值分别为 3.1 nM 和 6.1 nM。Quiflapon 可以诱导细胞凋亡 (apoptosis)。
研究领域:Immunology/Inflammation | Apoptosis
In Vitro: Quiflapon is a potent inhibitor of leukotriene (LT) biosynthesis in intact human and elicited rat polymorphonuclear leukocytes (PMNLs) (IC50 values 3.1 and 6.1 nM, respectively) and in human, squirrel monkey, and rat whole blood (IC50 values 510, 69, and 9 nM, respectively). Quiflapon has no effect on rat 5-lipoxygenase. Quiflapon has a high affinity for 5-lipoxygenase activating protein (FLAP) as evidenced by an IC50 value of 1.6 nM in a FLAP binding assay and inhibition of the photoaffinity labelling of FLAP by two different photoaffinity ligands. Inhibition of activation of 5-lipoxygenase was shown through inhibition of the translocation of the enzyme from the cytosol to the membrane in human PMNLs.
In Vivo: Quiflapon is a potent inhibitor of LT biosynthesis in vivo, first, following ex vivo challenge of blood obtained from treated rats and squirrel monkeys, second, in a rat pleurisy model, and, third, as monitored by inhibition of the urinary excretion of LTE4 in antigen-challenged allergic sheep. Inhibition of antigen-induced bronchoconstriction by Quiflapon is observed in inbred rats pretreated with methysergide, Ascaris-challenged squirrel monkeys, and Ascaris-challenged sheep (early and late phase response) [1]. Pups were treated with either vehicle or Quiflapon 10, 20, or 40 mg/kg subcutaneously daily for days 1-4, 5-9, or 10-14. On day 14, the lungs were inflated, fixed, and stained for histopathological and morphometric analyses. Hyperoxia groups treated with Quiflapon untreated hyperoxia groups showed definite evidence of aberrant alveolarization but no inflammation.
相关产品:Bioactive Compound Library Plus | Apoptosis Compound Library | Immunology/Inflammation Compound Library | Orally Active Compound Library | Targeted Diversity Library | Human Metabolite Library | Heterocyclic Compound Library | Highly Selective Inhibitors Library | Highly Selective Activators Library | Cell Death Library | MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | LY294002 | Tamoxifen | Paclitaxel | Y-27632 | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | SB-431542 | Actinomycin D | Deferoxamine mesylate | Bortezomib | 5-Fluorouracil | Trametinib | Sorafenib | Oxaliplatin | Gemcitabine | Temozolomide | Rotenone | Mdivi-1 | Elesclomol | Ruxolitinib | Decitabine | SP600125 | MK-2206 dihydrochloride | Etoposide | Monomethyl auristatin E
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料


















